Progress in Rectal Cancer Treatment

Table 4

Results of local excision following neoadjuvant (C)RT.

Study	Year	𝑁	cT stage	%cN+	(C)RT	LE technique	pCR	LR	OS	DFS
Garcia-Aguilar et al. [103]	2012	77	T2	0%	50.4–54 Gy with CAPOX	TAE, TEM	44%	—	—	—
Yeo et al. [104]	2010	11	T3	45%	50.4 Gy with 5FU, CAP, or CapIri	TAE	72%	9%	88.9% at 5 y	81.8% at 5 y
Callender et al. [105]	2010	47	T3	27.6%	45–52.5 Gy with 5FU	87% TAE, 13% Kraske	49%	10.6 at 10 y	74% at 10 y	76% at 10 y
Kundel et al. [106]	2010	20			50.4–54 Gy with 5FU	TAE	70%	0%	100% at 5 y	100% at 5 y
Bujko et al. [107]	2009	31	T1–T3	0%	5 × 5 Gy	39% TEM, 57% TAE,	35%	7%	—	—
		13			55.8 Gy with 5FU	4% Kraske	54%
Huh et al. [108]	2008	9	T2,T3	33%	45–50.4 Gy with oral 5FU	TAE	44%	11% at 10 y	89% at 10 y	78% at 10 y
Nair et al. [109]	2008	44	T2,T3	25%	50.4 Gy with 5FU	TAE (11% salvage)	57%	16%	81% at 5 y	—
Guerrieri et al. [110]	2008	196	T2,T3	0%	50.4 Gy, some with 5FU	TEM	17%	4%	—	95% (T2), 87% (T3) at 3 y
Park et al. [111]	2007	7	T2,T3	0%	45 Gy with 5FU	TAE	43%	0%	No events	No events
Caricato et al. [112]	2006	8	T2–T4	25%	45 Gy with 5FU + cisplatin	62% TEM, 38% TAE	37%	12%	No events	No events
Bonnen et al. [113]	2004	26	T3	4%	45–52.5 Gy with 5FU	88% TAE, 12% Kraske	54%	6% at 5 y	86% at 5 y	80% at 5 y
Ruo et al. [114]	2002	10	T2,T3	—	36–50.4 Gy, with 5FU	TAE	30%	20%	78% at 2 y	—
Schell et al. [115]	2002	11	ycT0,T1	27%	45 Gy with 5FU	TAE	73%	0%	No events	1 pulm. Metastasis
Kim et al. [116]	2001	26	T2,T3	27%	45 Gy with 5FU	TAE	65%	4%*	—	—
Mohiuddin et al. [117]	1994	48	T1–T3	—	55 Gy	TAE	37%	11%	83% at 5 y	—

RT: radiotherapy; LE: local excision; TAE: transanal excision; TEM: transanal endoscopic microsurgery; pCR: pathological complete response; SPS: sphincter preserving surgery; OS: overall survival; DFS: disease-free survival; LR: local recurrence.
*In a patient with pPR refusing additional surgery.